Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease
AssigneeIsis Pharmaceuticals, Inc.
InventorMark K. Wedel
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5′-GCCCAAGCTGGCATCCGTCA-3′, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal.
Claims48
1-37. (canceled)
A method for sustained amelioration of at least one indication of ulcerative colitis in an individual comprising:
- rectally administering, at a frequency of not more than once every other day, a therapeutic dose of a composition comprising an antisense oligonucleotide about 15 to 30 nucleic acid base units in length to an individual, wherein the oligonucleotide specifically hybridizes with nucleotides 2114 to 2133 of SEQ ID 1;
- and
- monitoring the individual for the amelioration of at least one indication of ulcerative colitis.
A method for sustained amelioration of at least one indication of ulcerative colitis in an individual comprising:
- rectally administering, at a frequency of not more than once every other day, a therapeutic dose of a composition comprising an antisense oligonucleotide of SEQ ID 2;
- and
- monitoring the individual for the amelioration of at least one indication of ulcerative colitis.
A method for ameliorating at least one indication of ulcerative colitis in an individual comprising:
- rectally administering at a therapeutic dose of a composition comprising an antisense oligonucleotide about 15 to 30 nucleic acid base units in length and hydroxypropyl methylcellulose to an individual, wherein the oligonucleotide specifically hybridizes with nucleotides 2114 to 2133 of SEQ ID 1, and wherein the administration results in minimal systemic exposure to the oligonucleotide;
- and
- monitoring the individual for the amelioration of at least one indication of ulcerative colitis.
Dependencies are inferred from the claim text.